BIODISTRIBUTION AND PHARMACOKINETICS OF I-LABELED LEX 032, A RECOMBINANT HYBRID OF ANTICHYMOTRYPSIN

Pharmacokinetic and biodistribution studies were conducted in rats on a novel serine protease inhibitor, LEX 032, that was radiolabeled with 131I by the Bolton-Hunter reagent. LEX 032, a genetically engineered recombinant human nonglycosylated serpin, has been shown to have antiinflammatory properties in a number of animal models of inflammation and reperfusion injury. When 131I-LEX 032 was injected intravenously, a rapid whole body clearance of radioactivity was seen. Blood clearance followed a similar pattern. Forty-eight hours postinjection, 2.00 +/- 0.65 of the administered dose remained in the body. Greater than 59% of the radio-activity was excreted in the urine within the first 24 hr. Little radioactivity was found in the feces. With the exception of the thyroid, no significant organ-related uptake was noted. Radioactivity in the liver peaked at 20 min postinjection, with 1.00 +/- 0.13% administered dose/g and approximately 10% administered dose in the whole liver. At 1 hr, uptake in the kidney (9.30 +/- 1.52% administered dose/g) was the highest among all tissues, except for the thyroid. Gamma camera images were consistent with the biodistribution pattern. Pharmacokinetics and biodistribution were not affected by the dose of LEX 032 and were quite different from those of glycosylated wild type antichymotrypsin. These data indicate that LEX 032 exhibits the pharmacokinetics expected of a nonglycosylated 45 kDa protein.

[1]  A. M. Lefer,et al.  Novel recombinant serpin, LEX-032, attenuates myocardial reperfusion injury in cats. , 1996, The American journal of physiology.

[2]  A. M. Lefer,et al.  BENEFICIAL EFFECTS OF LEX032, A NOVEL RECOMBINANT SERINE PROTEASE INHIBITOR, IN MURINE TRAUMATIC SHOCK , 1995, Shock.

[3]  A. M. Lefer,et al.  Cardioprotection by a novel recombinant serine protease inhibitor in myocardial ischemia and reperfusion injury. , 1995, The Journal of pharmacology and experimental therapeutics.

[4]  J. Enghild,et al.  Complexes between serpins and inactive proteinases are not thermodynamically stable but are recognized by serpin receptors. , 1994, Journal of Biological Chemistry.

[5]  B. Cooperman,et al.  Conversion of alpha 1-antichymotrypsin into a human neutrophil elastase inhibitor: demonstration of variants with different association rate constants, stoichiometries of inhibition, and complex stabilities. , 1994, Biochemistry.

[6]  J. Enghild,et al.  Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. , 1991, Biochemistry.

[7]  S. Pizzo,et al.  Evaluation of the rapid plasma elimination of recombinant alpha 1-proteinase inhibitor: synthesis of polyethylene glycol conjugates with improved therapeutic potential. , 1990, Journal of Laboratory and Clinical Medicine.

[8]  S. Feldman,et al.  In vivo catabolism of α1-antichymotrypsin is mediated by the Serpin receptor which binds α1-proteinase inhibitor, antithrombin III and heparin cofactor II , 1988 .

[9]  M. Fournel,et al.  Preclinical evaluation of alpha-1-proteinase inhibitor. Pharmacokinetics and safety studies. , 1988, The American journal of medicine.

[10]  R. Carrell,et al.  Isolation and properties of recombinant DNA produced variants of human alpha 1-proteinase inhibitor. , 1985, The Journal of biological chemistry.

[11]  J. Harlan Leukocyte-endothelial interactions. , 1985, Blood.

[12]  S. Kondo,et al.  [Antithrombin III and heparin cofactor II]. , 1985, Rinsho byori. The Japanese journal of clinical pathology.

[13]  M A Shifman,et al.  The in vivo metabolism of antithrombin III and antithrombin III complexes. , 1982, The Journal of biological chemistry.

[14]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[15]  W. Hunter,et al.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. , 1973, The Biochemical journal.

[16]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[17]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. , 1992, Biotechnology.

[18]  S. Pizzo,et al.  Hepatocyte uptake of α1‐proteinase inhibitor‐trypsin complexes in vitro: Evidence for a shared uptake mechanism for proteinase complexes of α1‐proteinase inhibitor and antithrombin III , 1984 .

[19]  G. Salvesen,et al.  Human plasma proteinase inhibitors. , 1983, Annual review of biochemistry.